Skip to content

Study · Randomized controlled trial · n = 174 · 2023

12 results

Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5.

Wharton S, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, Garvey WT

Obesity (Silver Spring, Md.)18 Jan 2023Cited by 92 (Europe PMC)

PMID36655300 (opens in a new tab)DOI10.1002/oby.23673 (opens in a new tab)PepBankPUB-36655300
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity completing the eating questionnaire, mean body weight fell 14.8% with semaglutide 2.4 mg and 2.4% with placebo.

    In plain wordsIn adults with overweight or obesity, body weight fell 14.8% with semaglutide and 2.4% with placebo over two years.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change in questionnaire subgroup
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Measurements

    Body weight change
    −14.8%
    semaglutide
    Body weight change
    −2.4%
    placebo

    Source sentences

    Summary
    In participants completing the Control of Eating Questionnaire (semaglutide, n = 88; placebo, n = 86), mean body weight changes were -14.8% (semaglutide) and -2.4% (placebo).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, Craving Control scores improved with semaglutide versus placebo at weeks 20, 52 and 104.

    In plain wordsIn adults with overweight or obesity, semaglutide improved craving control more than placebo at weeks 20, 52 and 104.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedCraving Control score
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p < 0.05); and for hunger and fullness at week 20 (p < 0.001).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, Craving for Savory scores improved with semaglutide versus placebo at weeks 20, 52 and 104.

    In plain wordsIn adults with overweight or obesity, semaglutide improved savory cravings more than placebo at weeks 20, 52 and 104.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedCraving for Savory score
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p < 0.05); and for hunger and fullness at week 20 (p < 0.001).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, Positive Mood scores improved with semaglutide versus placebo at weeks 20 and 52.

    In plain wordsIn adults with overweight or obesity, semaglutide improved positive mood more than placebo at weeks 20 and 52.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedPositive Mood score
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p < 0.05); and for hunger and fullness at week 20 (p < 0.001).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, Craving for Sweet scores improved with semaglutide versus placebo at weeks 20 and 52.

    In plain wordsIn adults with overweight or obesity, semaglutide improved sweet cravings more than placebo at weeks 20 and 52.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedCraving for Sweet score
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p < 0.05); and for hunger and fullness at week 20 (p < 0.001).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, hunger scores improved with semaglutide versus placebo at week 20.

    In plain wordsIn adults with overweight or obesity, semaglutide improved hunger scores more than placebo at week 20.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedHunger score at week 20
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p < 0.05); and for hunger and fullness at week 20 (p < 0.001).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, fullness scores improved with semaglutide versus placebo at week 20.

    In plain wordsIn adults with overweight or obesity, semaglutide improved fullness scores more than placebo at week 20.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedFullness score at week 20
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Scores significantly improved with semaglutide versus placebo for Craving Control and Craving for Savory domains at weeks 20, 52, and 104 (p < 0.01); for Positive Mood and Craving for Sweet domains at weeks 20 and 52 (p < 0.05); and for hunger and fullness at week 20 (p < 0.001).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  8. 08HumanRandomized controlled trialMechanism

    In adults with overweight or obesity on semaglutide, improvements in craving domain scores were positively correlated with body weight reduction from baseline to week 104.

    In plain wordsIn adults with overweight or obesity on semaglutide, bigger craving improvements were linked to bigger weight loss over two years.

    Peptide
    Semaglutide
    Outcome
    Not applicableCorrelation of craving score improvement with weight reduction
    Study

    n = 174

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    Improvements in craving domain scores were positively correlated with reductions in body weight from baseline to week 104 with semaglutide.
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, scores for desire to eat salty and spicy food were significantly lower with semaglutide than with placebo at 104 weeks.

    In plain wordsIn adults with overweight or obesity, semaglutide lowered the desire for salty and spicy food more than placebo at two years.

    Peptide
    Semaglutide
    Outcome
    DecreaseDesire to eat salty and spicy food at week 104
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    At 104 weeks, scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (all p < 0.05).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, scores for cravings for dairy and starchy foods were significantly lower with semaglutide than with placebo at 104 weeks.

    In plain wordsIn adults with overweight or obesity, semaglutide lowered cravings for dairy and starchy foods more than placebo at two years.

    Peptide
    Semaglutide
    Outcome
    DecreaseCravings for dairy and starchy foods at week 104
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    At 104 weeks, scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (all p < 0.05).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, scores for difficulty in resisting cravings were significantly lower with semaglutide than with placebo at 104 weeks.

    In plain wordsIn adults with overweight or obesity, semaglutide made cravings easier to resist than placebo at two years.

    Peptide
    Semaglutide
    Outcome
    DecreaseDifficulty resisting cravings at week 104
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    At 104 weeks, scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (all p < 0.05).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.
  12. 12HumanRandomized controlled trialEfficacy outcome

    In adults with overweight or obesity, control of eating scores were significantly reduced with semaglutide versus placebo at 104 weeks.

    In plain wordsIn adults with overweight or obesity, semaglutide changed control of eating scores more than placebo at two years.

    Peptide
    Semaglutide
    Outcome
    DecreaseControl of eating score at week 104
    Study

    n = 174

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    2.4 mg once weekly · 104 weeksAs given in this study (human).

    Source sentences

    Summary
    At 104 weeks, scores for desire to eat salty and spicy food, cravings for dairy and starchy foods, difficulty in resisting cravings, and control of eating were significantly reduced with semaglutide versus placebo (all p < 0.05).
    3 context sentences
    Summary · context
    In STEP 5, adults with overweight/obesity were randomized 1:1 to semaglutide 2.4 mg or placebo, plus lifestyle modification, for 104 weeks.
    Summary · context
    A 19-item Control of Eating Questionnaire was administered at weeks 0, 20, 52, and 104 in a subgroup of participants.
    Summary · context
    P values were not controlled for multiplicity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT06426446

Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data

Assistance Publique - Hôpitaux de Parisn = 80est. 1 Jun 2024 to est. 1 Jun 2025

Obesity

Trial pageClinicalTrials.govUpdated 23 May 2024
CompletedPhase 3Results postedNCT03693430

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity

Novo Nordisk A/Sn = 3045 Oct 2018 to 23 Mar 2021

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 6 Jul 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.